CA 19-9 in pancreatic cancer

R. E. Ritts, H. A. Pitt

Research output: Contribution to journalArticle

Abstract

CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalSurgical Oncology Clinics of North America
Volume7
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Reference Values
Neoadjuvant Therapy
Physiologic Monitoring

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Ritts, R. E., & Pitt, H. A. (1998). CA 19-9 in pancreatic cancer. Surgical Oncology Clinics of North America, 7(1), 93-101.

CA 19-9 in pancreatic cancer. / Ritts, R. E.; Pitt, H. A.

In: Surgical Oncology Clinics of North America, Vol. 7, No. 1, 1998, p. 93-101.

Research output: Contribution to journalArticle

Ritts, RE & Pitt, HA 1998, 'CA 19-9 in pancreatic cancer', Surgical Oncology Clinics of North America, vol. 7, no. 1, pp. 93-101.
Ritts, R. E. ; Pitt, H. A. / CA 19-9 in pancreatic cancer. In: Surgical Oncology Clinics of North America. 1998 ; Vol. 7, No. 1. pp. 93-101.
@article{061538177b9e4e828d9d508fa6057766,
title = "CA 19-9 in pancreatic cancer",
abstract = "CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.",
author = "Ritts, {R. E.} and Pitt, {H. A.}",
year = "1998",
language = "English (US)",
volume = "7",
pages = "93--101",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - CA 19-9 in pancreatic cancer

AU - Ritts, R. E.

AU - Pitt, H. A.

PY - 1998

Y1 - 1998

N2 - CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.

AB - CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031886205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031886205&partnerID=8YFLogxK

M3 - Article

C2 - 9443988

AN - SCOPUS:0031886205

VL - 7

SP - 93

EP - 101

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 1

ER -